Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 0.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,576 shares of the biotechnology company’s stock after buying an additional 8 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in United Therapeutics Corporation were worth $853,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Focused Wealth Management Inc lifted its position in shares of United Therapeutics Corporation by 17.5% during the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 140 shares during the period. Daiwa Securities Group Inc. lifted its position in shares of United Therapeutics Corporation by 17.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 200 shares during the period. Eagle Global Advisors LLC bought a new stake in shares of United Therapeutics Corporation during the 2nd quarter valued at $206,000. Clarity Capital KCPS Ltd. bought a new stake in shares of United Therapeutics Corporation during the 1st quarter valued at $230,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of United Therapeutics Corporation by 4.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 95 shares during the period.

COPYRIGHT VIOLATION NOTICE: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Raises Holdings in United Therapeutics Corporation (UTHR)” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/09/14/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-raises-holdings-in-united-therapeutics-corporation-uthr.html.

UTHR has been the subject of a number of recent analyst reports. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, UBS AG reiterated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company’s stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus price target of $134.50.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 123.18 on Thursday. The company’s 50 day moving average price is $129.61 and its 200 day moving average price is $130.11. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The company has a market capitalization of $5.35 billion, a P/E ratio of 14.29 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. United Therapeutics Corporation’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.42 earnings per share. Analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

In related news, CEO Martine A. Rothblatt sold 1,234 shares of United Therapeutics Corporation stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $132.32, for a total transaction of $163,282.88. Following the completion of the sale, the chief executive officer now owns 1,374 shares of the company’s stock, valued at $181,807.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher Causey sold 580 shares of United Therapeutics Corporation stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the sale, the director now directly owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,940 shares of company stock valued at $3,128,239. 7.80% of the stock is owned by company insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.